https://www.selleckchem.com/pr....oducts/semaxanib-su5
tion with physiologic growth in patients with SCS devices or foraminal extrusion in patients with dorsal root ganglion stimulation devices. There exist children with chronic pain refractory to standard of care approaches who could be considered for neuromodulation interventions. The existing data, which was limited and from a low tier of evidence, suggest that these interventions are relatively safe and provide meaningful pain reduction and functional improvements. While not previously reported, we recommend careful considerati
Beğen
Yorum Yap
Paylaş
